UCP2 and breast carcinoma: In the present study, we showed for the first time that trastuzumab treatment induced elevated expression of UCP-2, probably because of HER2 phosphorylation, using samples from HER2-positive breast cancer patient received trastuzumab neoadjuvant therapy.